PBI News

Press Releases
Pacific Biometrics Reports Third Quarter and Nine-Month Operating Results
Complete press release

PBI Published
Effects of Atorvastatin on Bone in Postmenopausal Women with Dyslipidemia: A Double-Blind, Placebo-Controlled, Dose-Ranging Trial
Click here for the complete article.

Stock Quote
PBI Listed
OTCBB: PBME

PBI on the road
Meet us at our next conference:
ACR/ARHP Annual
Scientific Meeting

October 17-21, 2009
Philadelphia, PA

To learn more about the event
click here.

The Value of Expertise

PBI has the best available methods and technologies. These provide unsurpassed quality and accuracy for clinical research. Since 1989 , PBI has supported hundreds of clinical trials for many major pharmaceutical, diagnostic, and biotechnology companies.

Specialty Central Laboratory: Leader in Setting Industry Standards

PBI provides comprehensive laboratory support for pharmaceutical and diagnostic product research. PBI has established a world-wide reputation for expertise in lipid and bone biomarkers as well as diabetes, arthritis, and inflammatory assessments. PBI is actively involved in researching, developing, and standardizing key assays for chronic diseases.

Immunogenicity and Clinical Biomarker Testing

PBI’s wholly owned subsidiary, Pacific Biomarkers, Inc compliments the Company’s current service capabilities. Designed primarily to support clinical development of biotherapeutics, these services include validation of ligand-binding assays for immunogenicity testing, novel biomarkers, and cell based assay development in a GLP environment.